Non-communicable diseases
V-Bio Ventures portfolio company Confo Therapeutics Announces Global Licensing Agreement with Lilly for Peripheral Pain Candidate, CFTX-1554
Confo to receive upfront and milestone payments totaling $630M Company is eligible for up to $590M in additional milestones if […] March 2, 2023 · V-Bio VenturesCMT Research Foundation (USA) collaborates with Augustine Therapeutics on new therapy against Charcot-Marie-Tooth disease
Leuven, Belgium, 02 March 2023 – Augustine Therapeutics announces a collaboration with the Charcot-Marie-Tooth Research Foundation (CMTRF) in the USA. CMTRF […] March 2, 2023 · Turnstone Communications
Coave Therapeutics: redecorating viral vectors for improved gene therapies
Coave Therapeutics is a French biotech developing gene therapies for neurodegenerative and ocular diseases. The company has developed a technology […] January 25, 2023 · V-Bio Ventures
The chaos of choice: how do people pick their food products?
Every family needs groceries, and most people regularly venture to the supermarket to gather supplies. If researchers can help shoppers […] January 25, 2023 · SciMingo
Cancer vaccines: not only treating tumors, but preventing them too
The COVID-19 pandemic has brought vaccines back into the drug development spotlight, and mRNA vaccines are stealing the show with […] November 23, 2022 · V-Bio Ventures
New personalized cancer vaccine in the making thanks to unique Belgian collaboration
The young Belgian start-up Persomed is unique – it was founded in 2020 by four partners each with relevant expertise […] November 23, 2022 · BioVox
Marfan patients team up with researchers to catch their silent killer
The world’s undiagnosed Marfan patients often go through life unaware of the hidden killer lurking in their DNA – a […] November 23, 2022 · SciMingoRejuvenate Biomed’s newly appointed Clinical Advisory Board endorses Clinical Phase 2b strategy in sarcopenia
Diepenbeek, Belgium, 15 November 2022 – Rejuvenate Biomed NV (“Rejuvenate”), a biomedical company developing novel combination drugs for age-related diseases, […] November 15, 2022 · Turnstone CommunicationsIntressa Vascular secures EUR 18 million in financing to support the development of its multilayer Allay™ Aortic Stent for the treatment of aortic dissection
Intressa Vascular is using its proprietary stent braiding technology to develop an innovative multilayer stent for the treatment of aortic […] October 25, 2022 · Turnstone Communications
Gene therapy challenges and the solutions in sight
Dr. Federico Mingozzi is the CSO of Spark Therapeutics, the company behind Luxturna – the world’s first FDA-approved gene therapy […] October 19, 2022 · BioVox
Picking up early signals: SPINOVIT to prevent cardiovascular diseases with new monitoring method
Preventing cardiovascular diseases before the first symptoms arise? That’s the ambition of SPINOVIT – a Louvain-La-Neuve company using a new […] October 19, 2022 · BioVox
From pattern to patient: microbiome research needs to bridge the gap to the clinic
The microbiome has been a trending scientific topic in recent years. Researchers have uncovered correlations between the human microbiome and […] September 7, 2022 · BioVox